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Prognostic value of serum C-reactive protein (CRP) and cytokeratin 
19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) 
in surgically treated patients with non-small cell lung cancer
Znaczenie rokownicze surowiczego stężenia białka C-reaktywnego (CRP)  
i fragmentów cytokeratyny 19 (Cyfra 21-1), ale nie antygenu rakowopłodowego (CEA)  
u chorych leczonych operacyjnie z powodu niedrobnokomórkowego raka płuca
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Abstract
Introduction: The aim of the study was to assess the prognostic value of cytokeratin 19 fragments (Cyfra 21-1), carcinoembryonic 
antigen (CEA) and C-reactive protein (CRP) in surgically treated NSCLC patients. 
Material and methods: 50 NSCLC patients (25 adenocarcinoma, 21 squamous cell and 4 adenosquamous), clinical stages I and 
II, age 42–89 years, entered the study. CEA, Cyfra 21-1 and CRP concentrations were measured in serum taken before surgery, 
CEA and Cyfra 21-1 in 50 patients, CRP — in 46 patients. The survival was calculated from the date of surgical treatment until 
death or until the end of the observation time. The results were expressed as medians (95%CI). 
Results: Cyfra 21-1 concentration was 2.1 (0.7–14.5) ng/mL. Survival time in the patients with Cyfra 21-1 ≤ 2 ng/mL, and > 2 ng/ 
/mL was 79 (14.85–88.2) and 29 (5.7–87.6) months, (p < 0.026). CEA concentration was 2.68 (0.87–72.7) ng/mL, significantly 
higher in adenocarcinoma than in squamous cell lung cancer — 4.38 ng/mL (1.67–41.35) vs. 2.2 ng/mL (1.0–6.1), p = 0.002. 
CRP concentration was 5.45 (0–122.6) mg/L. Significant dependence was found between CRP and pathological tumour size (pT). Median 
CRP values in pT1, pT2 and pT3+4 tumours were: 2.8 mg/L, 6.9 mg/L and 23.5 mg/L, respectively. Survival time of the patients with CRP 
≤ 10 mg/L and CRP > 10 mg/L was 79 (14.85–88.2) and 29.5 (5.7–87.6) months, respectively (p = 0.045). CRP > 10 mg/L and Cyfra 
21-1 > 2 ng/mL were the only significant preoperative prognostic indicators (HR 2.08 and 2.04, respectively). Among the postoperative 
parameters, pathological stage of disease (p-stage) and pT were the significant prognostic indicators (HR 2.1 and 2.42, respectively). 
Conclusions: In the present study, concerning surgically treated NSCLC patients, preoperative CRP > 10 mg/L and Cyfra 21-1 > 
2 ng/mL were the only negative prognostic indicators, while pT and p-stage were significant postoperative prognostic indicators. 
Key words: non-small cell lung cancer, prognosis, cytokeratins, carcinoembryonic antigen, c-reactive protein, surgical treatment
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Streszczenie
Wstęp: Celem pracy była ocena znaczenia rokowniczego przedoperacyjnych stężeń : fragmentów cytokeratyny 19 (Cyfra 21-1), 
antygenu rakowo-płodowego (CEA) i białka C-reaktywnego (CRP) w surowicy u chorych operowanych z powodu NDRP.
Materiał i metody: Badaniem objęto 50 chorych, w wieku 42–89 lat, w I i II klinicznym stadium zaawansowania NDRP, 
25 chorych na gruczolakoraka, 21 na raka płaskonabłonkowego i 4 na raka gruczołowo-płaskonabłonkowego. Stężenie CEA, 
Cyfra 21-1 i CRP oceniano w surowicy pobranej przed zabiegiem operacyjnym: CEA i Cyfra 21-1 — u 50 chorych, CRP — 
u 46 chorych. Czas przeżycia mierzono od daty zabiegu do zgonu lub do końca obserwacji. Wyniki podawano jako mediany 
(95%CI).
Wyniki: Stężenie Cyfra 21-1 wynosiło 2,1 (0,7–14,5) ng/ml. Czas przeżycia chorych z Cyfra 21-1 ≤ 2 ng/ml i > 2 ng/ml 
wynosił odpowiednio: 79 (14,85–88,2) i 29 (5,7–87,6) miesiąca, p < 0,026. 
Stężenie CEA wynosiło 2,68 (0,87–72,7) ng/ml, i było istotnie wyższe u chorych na gruczolakoraka w porównaniu z chorymi 
na raka płaskonabłonkowego — 4,38 (1,67–41,35) v. 2,2 (1,0–6,0) ng/ml, p = 0,002. 
Stężenie CRP wynosiło 5,45 (0–122,6) mg/l. Stwierdzono zależność pomiędzy CRP a patologicznym wymiarem guza. Mediana 
stężenia CRP w grupach pT1, pT2 i pT3+4 wynosiła odpowiednio: 2,8 mg/l, 6,9 mg/l and 23,5 mg/L (p < 0,05). Czas przeżycia 
chorych ze stężeniem CRP ≤ 10 mg/l i > 10 mg/l wynosił odpowiednio: 79 (14,85–88,2) i 29,5 (5,7–87,6) miesięcy (p = 0,045). 
CRP > 10 mg/l i Cyfra 21-1 > 2 ng/ml były jedynymi przedoperacyjnymi parametrami o istotnym znaczeniu rokowniczym 
(HR odpowiednio 2,08 i 2,42). Wśród parametrów pooperacyjnych istotne znaczenie rokownicze posiadały: stopień zaawanso-
wania patologicznego NDRP i wymiar guza w badaniu patologicznym (HR 2,1 i 2,42). 
Wnioski: W badanej grupie chorych na NDRP, spośród parametrów przedoperacyjnych tylko CRP > 10 mg/l i Cyfra 21-1 
> 2 ng/ml były negatywnymi czynnikami rokowniczymi, spośród parametrów pooperacyjnych — wymiar guza i stopień 
zaawansowania patologicznego NDRP. 
Słowa kluczowe: rak niedrobnokomórkowy, rokowanie, cytokeratyny, antygen rakowo-płodowy, białko C-reaktywne, leczenie 
operacyjne
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Introduction
Surgical treatment in the early stage of non
-small cell lung cancer (NSCLC) is associated with 
the best prognosis. Current 5-year survival rates 
are 50–70% in pathological stage I of the disease 
and 43–61% in stage II [1]. Despite extensive pre-
operative evaluation, still a significant proportion 
of the patients are diagnosed with pathological 
stage III disease after surgery. Such a finding 
is combined with substantially worse survival 
(5-year survival rates — 10–30%), even with the 
use of adjuvant therapy [2].
Stage of the disease is the strongest progno-
stic indicator; nevertheless, other prognostic 
factors such as age, tumour histology, lymphatic 
and blood vessels involvement are described in 
the literature [3, 4].
The role of preoperative assessment of tumo-
ur markers and inflammatory proteins as progno-
stic indicators is still not established.
The aim of the present study was to assess 
the value of preoperative tumour markers 
[cytokeratin 19 fragments (Cyfra 21-1), carci-
noembryonic antigen (CEA)] and C-reactive 
protein (CRP) in predicting long-term survi-
val in surgically treated non-small cell lung 
cancer patients.
Material and methods
Fifty consecutive NSCLC patients referred in 
2004 to the Department of Thoracic Surgery of 
the National Institute of Tuberculosis and Lung 
Diseases were prospectively enrolled into the 
study group. Written consent for participation 
in the study was obtained in all of them. The 
group included 38 males and 12 females, and 
median age was 65 years (range 42–89 years). 
Histological types of tumours, according to WHO 
classification from 2004 [5], were as follows: 
adenocarcinoma — in 25 patients, squamous 
cell lung cancer — in 21, adenosquamous lung 
cancer — in 4 patients. Preoperative staging was 
based on chest and upper abdomen computed 
tomography (CT), fibre-optic bronchoscopy and 
abdomen ultrasonographic examination. Brain 
CT scan was performed in four patients due 
to clinical suspicion of CNS metastases — the 
results were negative in all of them. Mediasti-
noscopy was performed in six patients with 
the suspicion of N2 disease based on chest 
CT (mediastinal lymph nodes enlargement 
> 1 cm in the short axis). The results were 
negative in all of them. The clinical staging 
(including the negative result of mediastino-
scopy), according to WHO sixth edition [6], 
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was: Ia in 12 patients, Ib in 26 patients, IIa in 
3 patients and IIb in 9 patients. 
Surgical treatment consisted of the following: 
lobectomy in 42 patients, bilobectomy in 1 pt and 
pneumonectomy in 7 patients. 
Pathological stage of the disease was as follows: 
Ia in 13 patients, Ib in 20, IIb in 9 patients, IIIa in 
4, IIIb in 3 and IV (metastases to the other lobe) in 
1 pt. Pathological tumour size (pT) was: pT1 in 13 
patients, pT2 in 32, pT3 in 2, and pT4 in 3 patients. 
The degree of differentiation of lung cancer 
was determined in 47 tumours: 14 were poorly 
differentiated (G3), 29 were moderately differen-
tiated (G2) and 4 were well differentiated (G1). 
Mean (± SD) and median (95%CI) percentage of 
necrotic cells were 21.74% ± 16.9% and 20% 
(0–80)%, respectively. 
The patients in whom pathological stages 
IIIa–IV of NSCLC were recognised after surgical 
treatment received adjuvant therapy (chemo ± 
radiotherapy).
Carcinoembryonic antigen (CEA) and cyto-
keratin 19 fragment (Cyfra 21-1) concentrations 
were measured in serum taken before surgery and 
before mediastinoscopy. Cobas Core immunoas-
say was used. The cut-off values provided by the 
assay’s manufacturer were applied: 5 ng/mL for 
CEA and 3.3 ng/mL for Cyfra 21-1. Serum CRP was 
assessed in 46 patients by Hitachi analyser. The 
cut off value was 5 mg/L. The CEA, Cyfra 21-1 and 
CRP values with highest prognostic significance 
were identified with the use of ROC curves.
The survival time was calculated from the 
date of surgical treatment until death or until the 
end of observation time (five years). 
Kruskal-Wallis one-way analysis of variance 
(on ranks) was used to compare marker values in 
different subgroups of patients. Death hazard ratio 
(HR) was assessed with single and multiple regres-
sion analysis. P < 0.05 was considered significant. 
Results
Median survival in the presented group of 
patients was 72.5 (4–108) months. The percenta-
ges of 1-, 2-, 3-, 4- and 5-year survival were: 88%, 
72%, 60%, 54% and 54%, respectively. 
Median preoperative serum Cyfra 21-1 con-
centration was 2.1 (95%CI 0.7–14.5) ng/mL. In 
16/50 patients (32%) Cyfra 21-1 values exceeded 
3.3 ng/mL. A tendency towards higher Cyfra 21-1 
values in the patients with higher pathological sta-
ges of the disease, comparing to the patients with 
lower stages of the disease, was found (Table 1). 
Median Cyfra 21-1 in stages Ia–IIb was 2.03 
(95%CI 1–6.76) ng/mL, and in stages III–IV it was 
3.6 (95%CI 1–14.5) ng/mL (p = 0.1). The values of 
Cyfra 21-1 did not correlate with the histological 
type of tumour (Table 2) nor with the percentage 
of tumour necrosis. According to ROC analysis, 
the Cyfra 21-1 value with optimal prognostic 
significance was 2 ng/mL. Median survival times 
in the patients with Cyfra 21-1 < = 2 ng/mL 
(23 patients) and > 2 ng/mL (27 patients) were 
79 (95%CI 14.85–88.2) months and 29 (95%CI 
5.7–87.6) months, respectively (p < 0.026). The 
survival curves of the patients with Cyfra 21-1 ≤ 
2 ng/mL and > 2 ng/mL are presented in Figure 1. 
Median preoperative serum CEA concen-
tration was 2.68 (95%CI 0.87–72.7) ng/mL. CEA 
exceeding 5 ng/mL was found in 11/50 patients 
(22%). CEA serum concentration depended on the 
histological type of tumour (Table 2). Significan-
tly higher median serum CEA was found in the 
patients with adenocarcinoma, comparing to the 
patients with squamous cell lung cancer — 4.38 
Table 1.  Cyfra 21-1, CEA and CRP according to the pathological stage of the disease in 50 NSCLC patients treated  
with surgery
Factor No Cyfra 21-1 (ng/mL)
Median (95%CI)
CEA (ng/mL)
Median (95%CI)
CRP (mg/L)*
Median (95%CI)
p-stage
Ia
Ib
IIb
IIIa
IIIb
IV
13
20
 9
 4
 3
 1
1.8 (0.75–3.5)
2.16 (1–10.45)
1.93 (1.3–5.77)
4.6 (1–7.1)
2.9 (1.8–14.5)
 2.61
2.8 (1.4–15.02)
2.58 (0.94–24.4)
2.6 (1–72.7)
2.77 (1.8–4.3)
1.5 (1–3.3)
 9.57
2.8 (0.06–60.99)
9.4 (1.49–74.78)
12.4 (0.2–86.3)
0.1 (0–23.5)
50.8 (2.4–122.6)
 6.9
Ia–IIb
III–IV
42
 8
2.03 (1–6.76)
3.6 (1–14.5)
2.68 (1–30.18)
2.72 (1–9.57)
5.45 (0.36–76.1)
4.65 (0–122.6)
p  0.1  0.54  0.5
*In 46 patients; p-stage — pathological stage of disease; CEA — carcinoembryonic antigen; CRP — C-reactive protein; NSCLC — non-small cell lung cancer
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Figure 1. Prognostic significance of preoperative serum Cyfra 21-1 in 50 non -small cell lung cancer patients
Table 2. Cyfra 21-1, CEA and CRP according to the histological type of tumour in 50 NSCLC patients
Histology No patients Cyfra 21-1 (ng/mL)
Median (95%CI)
CEA (ng/mL)
Median (95%CI)
CRP (mg/L)*
Median (95%CI)
Adeno 25 2.0 (1–5.22)  4.38 (1.67–41.35)  4.7 (0.42–83.99)
SCC 21 2.35 (1.1–13.8)  2.2 (1–6.1)  17.15 (0–99.88)
Others  4 3.43 (0.7–7.1)  3.22 (1.4–4.49) 1.3 (0.2–23.5)
p  0.27  0.002  0.112
*In 46 patients; CEA — carcinoembryonic antigen; CRP — C-reactive protein; NSCLC —  non -small cell lung cancer; adeno — adenocarcinoma; SCC — squamous 
cell lung cancer
ng/mL (95%CI 1.67–41.35) vs. 2.2 ng/mL (95%CI 
1.0–6.1), p = 0.002. No correlation was found 
between serum CEA and pathological stage of the 
disease (Table 1). ROC analysis failed to indicate 
an optimal prognostic CEA value. 
Median serum CRP was 5.45 (95%CI 0–122.6) 
mg/L. Values exceeding 5 mg/L were found in 
26/46 patients (60%). Significant dependence 
was found between serum CRP and pathological 
tumour size (pT). Median CRP values in pT1, pT2 
and pT3+4 tumours were: 2.8 mg/L, 6.9 mg/L and 
23.5 mg/L, respectively (p < 0.05) (Table 3). 
ROC analysis revealed that CRP > 10 mg/L 
was the optimal prognostic cut–off value. Median 
survival time of 28 patients with CRP ≤ 10 mg/L 
was 79 (14.85–88.2) months, and for 18 patients 
with CRP > 10 mg/L it was 29.5 (5.7–87.6) mon-
ths (p = 0.046). Survival curves of the patients 
with serum CRP ≤ 10 mg/L and > 10 mg/L are 
presented in Figure 2. 
Univariate analysis revealed that out of the 
factors known before lung surgery, only serum 
CRP > 10 mg/L and Cyfra 21-1 exceeding 2 ng/mL 
were significant prognostic indicators. No progno-
stic significance for patient age, sex, histological 
type of tumour and clinical stage of disease was 
found (Table 4). Among the parameters known 
after surgical treatment, pathological stage of the 
disease and pT value were significant prognostic 
indicators (Table 4). No prognostic significance 
of the percentage of necrotic tumour cells and 
the degree of tumour differentiation was found. 
Multivariate analysis taking into account 
only pretreatment prognostic parameters (Cyfra 
21-1 > 2 ng/mL and CRP > 10 mg/L) revealed 
that none of the markers was an independent 
prognostic factor. Multivariate analysis taking 
into account all significant prognostic variables, 
both pretreatment and post-treatment, revealed 
that only pathological stage of disease was an 
independent prognostic indicator (Table 4). 
Discussion
CRP is a marker of inflammation and tissue 
damage. Its prognostic significance is well esta-
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Table 3. CRP according to pathological size of tumour in 46 NSCLC patients
Factor No patients Median CRP mg/L Range mg/L CRP > 10 mg/L
pT1 12 2.8* 0.06–60.99 2/12
pT2 29 6.9* 0–83.17 12/29
pT3+4  5 23.5* 2.4–122.6 4/5
*p < 0.05; CEA — carcinoembryonic antigen; CRP — C-reactive protein; NSCLC —  non-small cell lung cancer; pT — pathological tumour size
Figure 2. Prognostic significance of preoperative serum C-reactive protein in 46 non-small cell lung cancer patients
blished in cardiovascular diseases [7]. Shields 
et al. found that inflammation score assessed by 
CRP, b-cell attracting chemokine 1 (macrophage
-derived chemokine) and interleukin 1 receptor 
antagonist provided good separation in 10-year 
lung cancer cumulative risk among current and 
former smokers and was of prognostic signifi-
cance [8]. 
A large epidemiological study of 33,567 
participants with various neoplastic diseases 
conducted by Ko et al. [9] indicated that CRP 
≥ 3 mg/L was associated with higher mortality 
in lung cancer. 
In the present study, preoperative serum 
CRP concentration > 10 mg/L was of prognostic 
significance, and the risk of death was twice as 
high in the group of patients with CRP > 10 mg/L 
comparing to the others. A similar observation 
concerning CRP prognostic value was made by 
O’Dowd et al. [10], who found significantly worse 
survival in patients with CRP exceeding 10 mg/L 
comparing to those with CRP equal to or lower 
than 10 mg/L (26.2 months and 75.9 months, re-
spectively). Hara et al. [11] found the prognostic 
significance of CRP > 5 mg/L in 203 patients who 
had undergone a curative resection of NSCLC. 
Tomita et al. [12] found in 301 resectable NSCLC 
patients that combined use of CRP and neutro-
phil-to-lymphocyte index could discriminate 
the groups with different 5–year survival rates 
(74.18% in case of both values low vs. 20% in 
case of both values high). Alifano et al. [13] fo-
und preoperative CRP exceeding 20 mg/L to be 
a significant prognostic indicator in 300 stage I or 
II NSCLC patients treated with surgery. 
Searching for a possible reason for the pro-
gnostic significance of CRP in NSCLC, we found 
in the present study a significant dependence 
between serum CRP and the pathological size 
of the tumour. Lee et al. [14] found a correlation 
between CRP and pathological tumour diameter, 
as well as between CRP and the signs of lympho-
vascular invasion, in 102 patients who underwent 
pulmonary resection. Alifano et al. found in lung 
cancer patients a correlation between serum CRP 
and the presence of chronic bronchitis, hypoal-
buminaemia, pathologic stage of the disease and 
peritumoural vascular emboli.
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Table 4.  Prognostic significance of different variables  
in 50 NSCLC patients (univariate and multivaria-
te analysis)
Univariate analysis HR p
CRP* 2,339 0.024
CRP > 10 mg/L* 2.08 0.043
CRP > 20 mg/L* 2.137 0.038
Cyfra 21-1 1.402 0.167
Cyfra 21-1 > 2 ng/mL 2.04 0.046
CEA 1.17 0.25
CEA > 5 ng/mL 0.46 0.647
C-stage 0.86 0.39
P-stage Ia–IIb vs. III–IV 2.7 0.009
P-stage Ia, Ib vs. IIb vs III–IV 2.1 0.04
P-stage 2.1 0.041
p-T 2.42 0.019
Histological type 1.39 0.17
Age 0.74 0.46
Gender 1.17 0.248
% of tumour necrosis  0.37 0.7
G1 vs. G2 vs. G3 0.275 0.785
Multivariate analysis
 (preoperative factors)*
HR p
CRP > 10 mg/L 1.39 0.173
Cyfra 21-1 > 2 ng/mL 1.52 0.136
Multivariate analysis  
(all prognostic factors)*
HR p
CRP > 10 mg/L 1.73 0.09
Cyfra 21-1 > 2 ng/mL 1.03 0.31
p–Stage Ia–IIb vs. III–IV 2.65 0.01
*in 46 patients; c-stage — clinical stage of disease; p-stage pathological stage 
of disease; p-T — pathological tumour size; G1-G3 degree of tumour differen-
tiation ; CEA — carcinoembryonic antigen; CRP — C-reactive protein; NSCLC 
—  non-small cell lung cancer
The other prognostic indicator found by our 
group was preoperative serum Cyfra 21-1 exce-
eding 2 ng/mL. Median survival in the groups 
with Cyfra 21-1 < 2 ng/mL and > 2 ng/mL were 
79 (95%CI 14.85–88.2) months and 29 (95%CI 
5.7–87.6) months, respectively (p < 0.026). Uni-
variate analysis revealed that the risk of death 
in the patients with serum Cyfra 21-1 > 2 ng/ 
/mL was twice as high as for those with Cyfra 
21-1 ≤ 2 ng/mL. 
The prognostic value of Cyfra 21-1 was 
investigated by many authors, and most of them 
confirmed the negative prognostic significance of 
abnormal Cyfra 21-1 value [15–20] (Table 5). In 
the reports concerning early-stage NSCLC treated 
with surgical resection, Cyfra 21-1 cut-offs used 
for assessment of prognosis were usually 2–2.8 
ng/mL [18, 19], and so were comparable to our 
cut off value of 2 ng/mL. The prognostic cut off 
value of Cyfra 21-1 in unresectable NSCLC was 
found to be much higher (4– 18 ng/mL) [21, 22].
Cyfra 21-1 was previously described as 
a marker of squamous cell lung cancer (SCC) [23]. 
Subsequently, an elevated level of the marker was 
also found in serum of patients with adenocarci-
noma and small cell lung cancer [22]. Similarly, 
in the present study we did not demonstrate 
significant differences between adenocarcinoma 
and SCC with respect to Cyfra 21-1 serum levels. 
An interesting study concerning the origin 
of Cyfra 21-1 in serum was presented Kosacka 
et al. [24], who compared tumour cytokeratin 19 
immunostaining with Cyfra 21-1 value in serum 
in each of the studied patients. The authors found 
that the lower the Cyfra 21-1 in tumour tissue, 
the higher it was in serum. This finding confirms 
early observations that Cyfra 21-1 is released into 
circulation from necrotic tumour cells. Hanada 
et al. [25] found that the combination of weak 
cytokeratin 19 tumour expression and high se-
rum Cyfra 21-1 levels was a predictor of poorer 
prognosis in 107 SCC patients. 
These data may indicate that Cyfra 21-1 
serum level reflects mainly the degree of tumour 
necrosis. Nevertheless, we could not demonstrate 
a correlation between serum Cyfra 21-1 and the 
percentage of tumour necrotic cells in the pre-
sented group of patients. 
In the present study, we did not find the 
prognostic significance of preoperative serum 
CEA. One of the reasons was that elevated CEA 
was found also in the patients with early-stage 
tumours (mainly of adenocarcinoma histology), 
who survived five years from surgical resection 
without a relapse. The other reason for the lack 
of prognostic significance of CEA in our study 
was probably the small number of patients en-
rolled. 
Most published data indicate the prognostic 
significance of CEA (Table 6) [26–33], but the 
majority of reports concern groups of patients 
with adenocarcinoma [28, 32] or with substantial 
adenocarcinoma predominance [18, 29, 31]. The 
authors of recently published articles have found 
that increased CEA concentration is a significant 
predictor of pN2 disease [1], tumour diameter and 
visceral pleural invasion [34], as well as recurren-
ce after surgery [35]. Tomita et al. [36] described 
the combination of high CEA and SUV max > 6.6 
on PET-CT scan as a prognostic variable.
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Table 5. Prognostic value of Cyfra 21-1 according to published data
Author Study group Histology Cyfra 21-1 cut off
ng/mL
5 years survivors p
Reinmuth 2002 [15] 67 NSCLC 
p-stage I–IIIa
31 SCC, 17 AD, 16 LA, 
3 Oth
 ≤ 3.57
 > 3.57
62%
33%
0.014
Mizuguchi 2007 [17] 272 NSCLC
p-stage I–IV
164 AD, 99 SCC, 5 LA, 
4 AD/SCC
≤ 2
 > 2
Multivariate analysis
HR 2.42
0.015
Suzuki 2007 [16] 101 NSCLC 
c-Stage I
AD 72, SCC 21, LA 7, 
Oth 1
 < 3.5
 ≥ 3.5
83.3%
50%
0.006
Matsuoka 2007 [18] 275 NSCLC
p-stage I
AD 193, SCC 71, oth 11  ≤ 2.8
 > 2.8
79.3%
64%
0.0041
Hanagiri 2011 [19] 264 AD
p-stage I
 ≤ 2
 > 2
92.8%
75.4%
0.0001
Park 2013 [20] 298 AD
p-stage I–III
 < 1.95
 ≥ 1.95
79.1%
58.4%
0.001
NSCLC —  non -small cell lung cancer; p-stage — pathological stage of disease; c-stage — clinical stage of disease; AD — adenocarcinoma; SCC — squamous cell 
lung cancer; LA — large cell lung cancer; oth — others
Table 6. Prognostic value of carcinoembryonic antigen (CEA) according to published data
Author Study group Histology CEA cut off ng/mL 5–years survivors p
Suzuki 1999 [26] 365 NSCLC
c-stage I
AD 267, oth 98  < 5
 ≥ 5
78.5%
53%
0.005
Sawabata 2002 [27] 297 NSCLC
c-stage I
AD 212, SCC 74, LA 
4, oth 7
 ≤ 7
 > 7
72%
49%
0.0001
Tomita 2004 [28] 271 AD
p-stage I–III
 ≤ 5
 > 5
77.6%
42.5%
0.001
Okada 2004 [29] 1000 NSCLC
c-stage I
694 AD, 260 SCC, 18 
LA, 28 Oth
 ≤ 5
 > 5
75.2%
53.8%
0.0001
Fukai 2007 [30] 45 NSCLC
p-stage II
64%AD, 29%SCC  < 5
 ≥ 5
79.9%
33.2%
0.0015
Matsuoka 2007 [18] 275 NSCLC
p-stage I
193 AD, 71 SCC, 11 oth  ≤ 5
 > 5
81.9%
59.8%
0.091
Kawachi 2009 [31] 815 NSCLC
c-stage I
541 Ad, 188 SCC, 39 
oth
 < 5
5–30
 > 30
76.7%
60%
31.3%
Igai 2012 [32] 122 AD p-stage IA  < 5
 ≥ 5
93.3%
33.3%
0.0001
Kato 2013 [33] 141 AD
p-stage I
 ≤ 2.5
 > 2.5
93%
59.4%
0.0001
NSCLC — non -small cell lung cance; p-stage — pathological stage of disease; c–stage — clinical stage of disease; AD — adenocarcinoma; SCC — squamous cell 
lung cancer; LA — large cell lung cancer; oth — others
On the other hand, Takahashi et al. [37], who 
examined CEA in 649 surgically treated patients, 
found that 7 out of 28 patients with serum CEA 
> 30 ng/mL were long-term survivors (> 4 years). 
This is similar to our observation that 6/11 pa-
tients with CEA > 5 ng/mL survived 5 years or 
longer.
Important new data concerning the relation 
between high CEA serum concentration and the 
presence of EGFR mutation in adenocarcinoma 
were published in 2007 by Shoji et al. [38] and 
were recently confirmed by Zhang et al. [39].
Summary
In the present study, concerning surgically 
treated NSCLC patients with clinical stage I and II 
of the disease, a preoperative CRP value exceeding 
10 mg/L and Cyfra 21-1 higher than 2 ng/mL were 
the only negative prognostic indicators. Patho-
Monika Szturmowicz et al., CRP, Cyfra 21-1 and CEA in surgically treated NSCLC
429www.pneumonologia.viamedica.pl
logical tumour size and p-stage of disease were 
significant postoperative prognostic indicators. 
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